title: Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men.
abstract: OBJECTIVE
  To conduct a study to determine whether diabetes treatment is associated with benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and progression in black and white men. Diabetes has been associated with BPH and LUTS in aging men.
  
  
  METHODS
  Using the Olmsted County Study of Urinary Symptoms and Health Status among Men and the Flint Men's Health Study, we examined how the use of medical therapy (eg, insulin regimens, oral hypoglycemics) related to changes in LUTS severity, maximal urinary flow rate measured by uroflowmetry, prostate volume determined by transrectal ultrasonography, and serum prostate-specific antigen concentrations.
  
  
  RESULTS
  Of the 2226 men participating in the Olmsted County Study of Urinary Symptoms and Health Status among Men and the Flint Men's Health Study, 186 men reported a history of diabetes, 76.9% of whom were treated with medical therapy. Overall, the men with diabetes had significantly greater odds of moderate/severe LUTS (age- and race-adjusted odds ratio 1.37, 95% confidence interval 1.00-1.87) compared with those without diabetes. However, among the diabetic men, those not taking medication had greater odds of moderate/severe LUTS than those taking medication. This association among men not taking medication was seen for 5 of the 7 individual symptoms. The prostate volume and prostate-specific antigen level were not significantly associated with diabetes treatment. No significant differences were observed for the annual change in BPH characteristics by diabetes treatment status.
  
  
  CONCLUSIONS
  These findings suggest that the presence of diabetes and subsequent poor glycemic control might be less related to prostate growth and more to the dynamic components of lower urinary tract function. Additional evaluations of the associations between glycemic control and BPH progression are warranted.
authors: Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109-2800, USA. asarma@umich.edu
authors: Aruna V
authors: AV
authors: Sarma
authors: Jennifer L
authors: JL
authors: St Sauver
authors: John M
authors: JM
authors: Hollingsworth
authors: Debra J
authors: DJ
authors: Jacobson
authors: Michaela E
authors: ME
authors: McGree
authors: Rodney L
authors: RL
authors: Dunn
authors: Michael M
authors: MM
authors: Lieber
authors: Steven J
authors: SJ
authors: Jacobsen
mesh_terms: D000328:Adult; D001741:Black or African American / Q000706:statistics & numerical data*; D017677:Age Distribution; D000368:Aged; D016022:Case-Control Studies; D015331:Cohort Studies; D016001:Confidence Intervals; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000208:ethnology; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D015995:Prevalence; D011470:Prostatic Hyperplasia / Q000453:epidemiology* / Q000208:ethnology / Q000209:etiology / Q000503:physiopathology; D012111:Residence Characteristics; D018570:Risk Assessment; D012720:Severity of Illness Index; D014481:United States / Q000453:epidemiology; D044465:White People / Q000706:statistics & numerical data*
chemical_list: D007004:Hypoglycemic Agents